拜耳通过进博会平台展示创新产品及解决方案

2018-11-05 美通社 美通社

随着首届中国国际进口博览会于上海中国国家会展中心正式拉开序幕,吸引全球众多企业参展,开启了世界上第一个以进口为主题的国家级展会,为参会国家和企业提供展示、交流和合作的机会。借此平台,作为在中国拥有超过130年历史的创新企业,拜耳也将通过这一平台展示发展成果,呈现一系列的产品和解决方案。 拜耳展台   拜耳展台 首届中国国际进口博览会于上海中国国家会展中心正式拉开序幕。借此平台,作为在

随着首届中国国际进口博览会于上海中国国家会展中心正式拉开序幕,吸引全球众多企业参展,开启了世界上第一个以进口为主题的国家级展会,为参会国家和企业提供展示、交流和合作的机会。借此平台,作为在中国拥有超过130年历史的创新企业,拜耳也将通过这一平台展示发展成果,呈现一系列的产品和解决方案。

拜耳展台
拜耳展台

 

拜耳展台
拜耳展台

首届中国国际进口博览会于上海中国国家会展中心正式拉开序幕。借此平台,作为在中国拥有超过130年历史的创新企业,拜耳也将通过这一平台展示发展成果,呈现一系列的产品和解决方案。

作为一家领先的医药保健与生命科学公司,拜耳自1882年开启与中国的贸易往来。在首届中国国际进口博览会上,坐落于医疗器械及医药保健展区、总面积达200平方米的拜耳展位将以“关注健康与营养”为主题,在展区内通过不同形式向观众展示处方药、健康消费品、作物科学以及动物保健业务的最新研究产品及发展理念,结合国家政策趋势和社会热点,展示出可持续发展主题以及跨境电商等全新业务领域。

中国是拜耳在全球非常重要的市场之一,秉承着“科技创造美好生活”的使命,拜耳始终关注中国市场的发展,随着中国成为世界上增长最快的市场之一,拜耳也逐步加大了在这里的的投入。在长期的发展过程中,拜耳不断积累适应中国市场的理念和实践,并且一直坚定不移地致力于参与到中国市场中,为中国的美好生活做出贡献。如在进博会中所展示的一样,拜耳紧随中国扩大开放的决心和战略布局,将充分利用政策优势和良好的市场环境,根据中国消费者的需求提供所需的产品和解决方案。

“中国国际进口博览会(CIIE)是中国政府强化和推进扩大对外开放政策的标志性举措。拜耳致力于在医疗保健和营养领域为提升人们生活质量做出贡献,我们有幸参与本次进口博览会并期待借此提升公众对我们使命的认知。进口博览会将为与会国家、企业及个人创造展示产品、技术、优势以及交流想法和寻求合作伙伴的机会。”拜耳集团大中华区总裁朱丽仙表示:“中国始终是,并将继续成为拜耳全球业务战略和增长的重要市场。我们相信拜耳正为中国发展贡献力量,进口博览也将提供绝佳机会,让我们把更多优质产品和解决方案带到中国来,满足中国患者、消费者和农民的需求,帮助他们提升生活品质。”  

本次进博会中,拜耳展台主要分为四个版块,包括处方药业务之健康医院主题,健康消费品业务之自我保健主题,作物科学业务之绿色农场主题,以及拜耳04勒沃库森俱乐部展示区域。在处方药领域,拜耳通过此次进口博览会平台,展现了公司在血管疾病、肿瘤、眼科等治疗领域的创新优势,以及全球先进的影像诊断解决方案,希望助力中国社会应对包括慢病、癌症等疾病所带来的重大健康挑战。在健康消费品领域,拜耳致力于关注自我保健,为消费者提供可信赖的非处方药产品和保健品,帮助大家预防疾病,关爱自身健康,提升生活品质。同时,拜耳也致力于数字化趋势和电子商务领域的不断创新,通过跨境电商业务,让中国的消费者们触手可及值得信赖的来自拜耳的健康消费品。根植中国农业60余年,拜耳的创新作物解决方案以可持续的方式,帮助种植户提升产量,提高生产效率,为大众提供安全、营养、可负担的粮食产品,同时兼顾环境。同时在水产养殖、宠物保健和农场畜牧等业务领域,也提供了全面地解决方案。    

改革开放以来,中国经济持续稳定发展,市场充满活力且潜力巨大,为外企在中国的发展创造了诸多机遇。本次进博会有利于促进世界各国加强经贸交流合作,促进全球贸易和世界经济增长,推动开放型世界经济发展。多年来,拜耳致力于在生命科学领域不断发展,将创新的产品带到中国来,未来,拜耳将继续扎根中国市场,服务于中国市场,将包括拜耳的创新精神、企业社会责任、拜耳04勒沃库森俱乐部代表的体育精神在内的理念共同融入到可持续发展和解决方案之中,在科技力量的带动下创想未来。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2080482, encodeId=0f57208048298, content=<a href='/topic/show?id=f22e320983f' target=_blank style='color:#2F92EE;'>#创新产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32098, encryptionId=f22e320983f, topicName=创新产品)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Oct 19 13:10:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988006, encodeId=b368198800669, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 15 12:10:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285662, encodeId=697e1285662b6, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318478, encodeId=f90113184e8de, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379848, encodeId=03ab13e984812, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351658, encodeId=93ad3516583a, content=共同发展,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Nov 05 21:27:39 CST 2018, time=2018-11-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2080482, encodeId=0f57208048298, content=<a href='/topic/show?id=f22e320983f' target=_blank style='color:#2F92EE;'>#创新产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32098, encryptionId=f22e320983f, topicName=创新产品)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Oct 19 13:10:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988006, encodeId=b368198800669, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 15 12:10:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285662, encodeId=697e1285662b6, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318478, encodeId=f90113184e8de, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379848, encodeId=03ab13e984812, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351658, encodeId=93ad3516583a, content=共同发展,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Nov 05 21:27:39 CST 2018, time=2018-11-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2080482, encodeId=0f57208048298, content=<a href='/topic/show?id=f22e320983f' target=_blank style='color:#2F92EE;'>#创新产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32098, encryptionId=f22e320983f, topicName=创新产品)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Oct 19 13:10:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988006, encodeId=b368198800669, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 15 12:10:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285662, encodeId=697e1285662b6, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318478, encodeId=f90113184e8de, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379848, encodeId=03ab13e984812, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351658, encodeId=93ad3516583a, content=共同发展,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Nov 05 21:27:39 CST 2018, time=2018-11-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2080482, encodeId=0f57208048298, content=<a href='/topic/show?id=f22e320983f' target=_blank style='color:#2F92EE;'>#创新产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32098, encryptionId=f22e320983f, topicName=创新产品)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Oct 19 13:10:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988006, encodeId=b368198800669, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 15 12:10:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285662, encodeId=697e1285662b6, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318478, encodeId=f90113184e8de, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379848, encodeId=03ab13e984812, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351658, encodeId=93ad3516583a, content=共同发展,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Nov 05 21:27:39 CST 2018, time=2018-11-05, status=1, ipAttribution=)]
    2018-11-07 ying_wu
  5. [GetPortalCommentsPageByObjectIdResponse(id=2080482, encodeId=0f57208048298, content=<a href='/topic/show?id=f22e320983f' target=_blank style='color:#2F92EE;'>#创新产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32098, encryptionId=f22e320983f, topicName=创新产品)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Oct 19 13:10:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988006, encodeId=b368198800669, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 15 12:10:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285662, encodeId=697e1285662b6, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318478, encodeId=f90113184e8de, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379848, encodeId=03ab13e984812, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351658, encodeId=93ad3516583a, content=共同发展,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Nov 05 21:27:39 CST 2018, time=2018-11-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2080482, encodeId=0f57208048298, content=<a href='/topic/show?id=f22e320983f' target=_blank style='color:#2F92EE;'>#创新产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32098, encryptionId=f22e320983f, topicName=创新产品)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Oct 19 13:10:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988006, encodeId=b368198800669, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 15 12:10:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285662, encodeId=697e1285662b6, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318478, encodeId=f90113184e8de, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379848, encodeId=03ab13e984812, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Wed Nov 07 12:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351658, encodeId=93ad3516583a, content=共同发展,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Nov 05 21:27:39 CST 2018, time=2018-11-05, status=1, ipAttribution=)]
    2018-11-05 医者仁心5538

    共同发展,造福人类

    0

相关资讯

拜耳大力投入差异化药物研发产品线

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_

CFDA批准拜耳多吉美®(索拉非尼)用于甲状腺癌的治疗

甲状腺癌是最常见的内分泌恶性肿瘤。全球范围内每年有超过213,000例甲状腺癌新发病例,每年约35,000人死于甲状腺癌。近日,拜耳宣布国家食品药品监督管理局(CFDA)批准口服多激酶抑制剂多吉美(索拉非尼)用于治疗局部复发或转移的进展性的放射性碘难治性(RAI)分化型甲状腺癌(DTC)。CFDA对索拉非尼的批准进行了优先审评,批准理由为与现有治疗手段相比具有明显治疗优势。在Ⅲ期DECISION(

十年 “走进西部”,拜耳全力支持中国基层医疗卫生服务

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li

英国推出拜耳的五年避孕药Kyleena

英国推出了一种新的长效可逆避孕法,该避孕方法可以防止意外怀孕长达5年。拜耳的宫内节育器可以通过持续释放一种低剂量的合成激素--一种名为左炔诺孕酮的孕激素--来防止怀孕。该系统通过使宫颈粘液增厚并使子宫内膜变薄来在局部起作用,在子宫中形成抑制精子功能和运动的环境。Bayer指出,在第三阶段的临床试验表明,它"无论年龄和性别,都是非常有效且耐受性良好的",其有效性率为99%,而异位妊娠、盆腔炎、子宫和

拜耳肝癌治疗新药在华获批上市

3月18日是“全国爱肝日”,在当天召开的“中国肝癌领导力论坛”上,拜耳宣布口服多激酶抑制剂拜万戈(瑞戈非尼)肝癌适应症在华上市。拜万戈于2017年12月经国家食品药品监督管理总局(CFDA)优先审评批准用于既往接受过索拉非尼治疗的肝细胞癌(HCC)患者,是十年来在华首个获批并上市的肝癌治疗新药。这是继全球首个获批用于晚期肝癌系统治疗药物——多吉美之后,拜耳在肝癌治疗领域的又一重大突破,也是中国肝癌

拜耳赢得欧盟监管机构对更广泛的Xarelto使用的认可

拜耳近日宣布欧洲药品管理局的人用药品委员会(CHMP)采取积极意见,将Xarelto扩大到动脉粥样硬化患者的治疗。该公司表示,如果更广泛的使用获得批准,大约3000万名患者可能从口服Xarelto(Xa抑制剂)中获益。